Trikafta is now approved for use in CF patients 12 years and older with at least one F508del mutation.
FDA Approves Cystic Fibrosis Drug Applicable For 90 Percent Of Patients
Trikafta is now approved for use in CF patients 12 years and older with at least one F508del mutation.